No mRNA Me-Too? CureVac Spies 2021 Launch For COVID-19 Vaccine
EU Backing Gives Company Options
Pfizer and Moderna have set a high bar, but CureVac's mRNA contender is buoyed by a big EU procurement deal and a favorable stability profile as it heads into pivotal trials.
You may also be interested in...
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.